⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772482 | 1.00 | — | — | |
| Acetamide SCHEMBL9932795 | 0.86 | ADORA2B (0.36) | — | |
| SCHEMBL16576781 | 0.71 | FTO (0.38) | — | |
| SCHEMBL29952353 | 0.69 | PIK3CG (0.39) | — | |
| SCHEMBL29557070 | 0.68 | EGFR (0.36) | — | |
| SCHEMBL16672156 | 0.67 | MAPT (0.32) | — | |
| SCHEMBL3058140 | 0.67 | PIN1 (0.33) | — | |
| SCHEMBL2042259 | 0.67 | HSP90AA1 (0.41) | — | |
| SCHEMBL2036215 | 0.67 | — | — | |
| Quinazoline SCHEMBL20919074 | 0.66 | EGFR (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 972 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043809-A1 | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury | NEW YORK UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| WO-2021097074-A1 | INTESTINAL ORGANOID CO-CULTURE SYSTEMS AND METHODS FOR TREATING OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH IMMUNE RESPONSE-MEDIATED TISSUE INJURY | NEW YORK UNIVERSITY (US) | 2021-05-20 | — | — | WO | claimed |
| US-20210139857-A1 | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury | NEW YORK UNIVERSITY | 2021-05-13 | — | — | US | claimed |
| US-20130303563-A1 | TREATMENT OF PERITONEAL INJURY USING JAK INHIBITORS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2013-11-14 | — | — | US | claimed |
| US-8507502-B2 | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-08-13 | — | — | US | claimed |
| EP-1121129-B1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | claimed |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-11-18 | — | — | US | claimed |
| EP-1449835-A2 | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-25 | — | — | EP | claimed |
| EP-1113801-A4 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL MYERS SQUIBB CO (US) | 2002-10-02 | — | — | EP | claimed |
| JP-2002524518-A | — | — | 2002-08-06 | — | — | JP | claimed |
| EP-1113801-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-11 | — | — | EP | claimed |
| US-6124306-A | Thioalkyl alpha substituted pyrimidine compounds | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-26 | — | — | US | claimed |
| EP-1034167-A1 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-13 | — | — | EP | claimed |
| WO-2000015230-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| WO-1999019304-A9 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | UPJOHN CO (US) | 1999-07-08 | — | — | WO | claimed |
| WO-1999019304-A2 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-22 | — | — | WO | claimed |
| EP-0824524-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035678-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | claimed |
| EP-0459611-A2 | Furopyrimidine derivatives | DOWELANCO (US) | 1991-12-04 | — | — | EP | claimed |
| US-4180577-A | ANTIINFLAMMATORY AGENTS, ANTI-EDEMA AGENTS | EISAI CO., LTD. (JP) | 1979-12-25 | — | — | US | claimed |